Puma Biotechnology (United States)
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018 · David M. Hyman, Sarina A. Piha‐Paul, et al. · Nature
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martín, Frankie A. Holmes, et al. · The Lancet Oncology
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2016 · Arlene Chan, Suzette Delaloge, et al. · The Lancet Oncology